GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (OTCPK:TLIS) » Definitions » Piotroski F-Score

TLIS (Talis Biomedical) Piotroski F-Score : 2 (As of Mar. 17, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Talis Biomedical has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Talis Biomedical's Piotroski F-Score or its related term are showing as below:

TLIS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 2   Max: 5
Current: 2

During the past 6 years, the highest Piotroski F-Score of Talis Biomedical was 5. The lowest was 2. And the median was 2.


Talis Biomedical Piotroski F-Score Historical Data

The historical data trend for Talis Biomedical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical Piotroski F-Score Chart

Talis Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 3.00 5.00 4.00

Talis Biomedical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 4.00 2.00 2.00

Competitive Comparison of Talis Biomedical's Piotroski F-Score

For the Medical Devices subindustry, Talis Biomedical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talis Biomedical's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Net Income was -15.682 + -13.46 + -13.035 + -8.849 = $-51.03 Mil.
Cash Flow from Operations was -11.144 + -11.357 + -6.427 + -11.33 = $-40.26 Mil.
Revenue was 0.076 + 0.151 + 0.073 + 0 = $0.30 Mil.
Gross Profit was 0.07 + 0.143 + 0.067 + 0 = $0.28 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Jun24) was
(123.076 + 107.228 + 94.674 + 82.494 + 72.699) / 5 = $96.0342 Mil.
Total Assets at the begining of this year (Jun23) was $123.08 Mil.
Long-Term Debt & Capital Lease Obligation was $15.88 Mil.
Total Current Assets was $63.60 Mil.
Total Current Liabilities was $8.20 Mil.
Net Income was -26.021 + -26.929 + -17.831 + -15.034 = $-85.82 Mil.

Revenue was 0.73 + 0.107 + 0.137 + 0.048 = $1.02 Mil.
Gross Profit was -0.506 + -2.225 + 0.117 + 0.041 = $-2.57 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was
(221.69 + 194.094 + 169.29 + 133.053 + 123.076) / 5 = $168.2406 Mil.
Total Assets at the begining of last year (Jun22) was $221.69 Mil.
Long-Term Debt & Capital Lease Obligation was $17.65 Mil.
Total Current Assets was $101.97 Mil.
Total Current Liabilities was $9.26 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Talis Biomedical's current Net Income (TTM) was -51.03. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Talis Biomedical's current Cash Flow from Operations (TTM) was -40.26. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=-51.026/123.076
=-0.41458936

ROA (Last Year)=Net Income/Total Assets (Jun22)
=-85.815/221.69
=-0.38709459

Talis Biomedical's return on assets of this year was -0.41458936. Talis Biomedical's return on assets of last year was -0.38709459. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Talis Biomedical's current Net Income (TTM) was -51.03. Talis Biomedical's current Cash Flow from Operations (TTM) was -40.26. ==> -40.26 > -51.03 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=15.877/96.0342
=0.16532652

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=17.648/168.2406
=0.10489739

Talis Biomedical's gearing of this year was 0.16532652. Talis Biomedical's gearing of last year was 0.10489739. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun24)=Total Current Assets/Total Current Liabilities
=63.601/8.196
=7.76000488

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=101.965/9.262
=11.00896135

Talis Biomedical's current ratio of this year was 7.76000488. Talis Biomedical's current ratio of last year was 11.00896135. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Talis Biomedical's number of shares in issue this year was 1.822. Talis Biomedical's number of shares in issue last year was 1.817. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.28/0.3
=0.93333333

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-2.573/1.022
=-2.51761252

Talis Biomedical's gross margin of this year was 0.93333333. Talis Biomedical's gross margin of last year was -2.51761252. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=0.3/123.076
=0.00243752

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun22)
=1.022/221.69
=0.00461004

Talis Biomedical's asset turnover of this year was 0.00243752. Talis Biomedical's asset turnover of last year was 0.00461004. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Talis Biomedical has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Talis Biomedical  (OTCPK:TLIS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Talis Biomedical Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Talis Biomedical Business Description

Traded in Other Exchanges
N/A
Address
1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
Executives
Andrew A Lukowiak officer: President, other: Chief Scientific Officer 1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich officer: Interim CFO CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser director, officer: President and CEO 561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan officer: Sr. Vice President, R&D 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Moody John Roger Jr officer: Chief Financial Officer 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062